Michael Bloch, MD, on Hypercholesterolemia: A Focus on PCSK9 Inhibitors

In this video, Michael Bloch, MD, talks about his session at the Cardiometabolic Risk Summit 2019, which reviewed the latest clinical data for PCSK9 inhibitors in lowering LDL-C and cardiovascular events, assessed current evidence for the optimum LDL-C goals for patients with hypercholesterolemia, and more.